Elara Securities has initiated a BUY rating on Alkem Laboratories with a target price of ₹6,533, according to reports from The Hindu BusinessLine. The brokerage's target represents a 26.5x FY29E core earnings plus cash per share valuation. At the current market price of ₹5,300, this suggests significant upside potential for investors.
As reported by The Hindu BusinessLine, Alkem Laboratories has established leadership across large acute therapies supported by established brands and a strong prescriber franchise. The company's increasing focus on chronic and specialty therapies is expected to improve the quality and consistency of domestic growth while reducing seasonality. Key growth drivers include investments across anti-diabetes, cardiac and CNS segments, with the semaglutide entry strengthening the diabetes franchise and providing participation in one of India's largest pharma product markets.
According to The Hindu BusinessLine, Alkem's US business has largely stabilised following the prolonged generic price-erosion cycle. The company plans a selective approach to new launches and differentiated products to support steady business pick-up. The upcoming launch of gJynarque (Tolvaptan) is expected to be a key growth driver for the US operations.
As reported by The Hindu BusinessLine, Alkem has expanded its business into medical devices in orthopaedics and cardiovascular areas through small domestic acquisitions. The company is further strengthening its franchise through the proposed acquisition of Swiss-based Occlutech. Additionally, Enzene BioSciences represents a new venture into biologics CDMO platform, though these ventures are currently loss-making but expected to break even in the next four-eight quarters.
According to The Hindu BusinessLine, Alkem currently trades at 32.3x FY27E and 25.0x FY28E core EPS, adjusted for cash per share. The brokerage's BUY rating and ₹6,533 target price reflect confidence in the company's diversification strategy and growth prospects across multiple therapeutic areas. The valuation multiple suggests market expectations for sustained earnings growth and successful execution of the company's strategic initiatives.
